Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet).
Walmsley
S L
SL
Department of Medicine, University of Toronto, Canada.
Chew
E
E
Read
S E
SE
Vellend
H
H
Salit
I
I
Rachlis
A
A
Fanning
M M
MM
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy*; D017245:Foscarnet; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000150:complications; D008297:Male; D008875:Middle Aged; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010746:Phosphonoacetic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012008:Recurrence; D012173:Retinitis / Q000150:complications / Q000188:drug therapy*
D000998:Antiviral Agents; D009943:Organophosphorus Compounds; D017245:Foscarnet; D010746:Phosphonoacetic Acid